These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 10733490)

  • 1. Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy.
    Lemoli RM; Martinelli G; Zamagni E; Motta MR; Rizzi S; Terragna C; Rondelli R; Ronconi S; Curti A; Bonifazi F; Tura S; Cavo M
    Blood; 2000 Apr; 95(7):2234-9. PubMed ID: 10733490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total therapy with tandem transplants for newly diagnosed multiple myeloma.
    Barlogie B; Jagannath S; Desikan KR; Mattox S; Vesole D; Siegel D; Tricot G; Munshi N; Fassas A; Singhal S; Mehta J; Anaissie E; Dhodapkar D; Naucke S; Cromer J; Sawyer J; Epstein J; Spoon D; Ayers D; Cheson B; Crowley J
    Blood; 1999 Jan; 93(1):55-65. PubMed ID: 9864146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study.
    Tribalto M; Amadori S; Cudillo L; Caravita T; Del Poeta G; Meloni G; Avvisati G; Petrucci MT; Pulsoni A; Leone G; Sica S; Martelli M; Tabilio A; Fioritoni G; Majolino I; Mandelli F
    Haematologica; 2000 Jan; 85(1):52-8. PubMed ID: 10629592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
    O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; Samson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A
    Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone.
    Desikan KR; Tricot G; Dhodapkar M; Fassas A; Siegel D; Vesole DH; Jagannath S; Singhal S; Mehta J; Spoon D; Anaissie E; Barlogie B; Munshi N
    Bone Marrow Transplant; 2000 Mar; 25(5):483-7. PubMed ID: 10713623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission.
    Nadal E; Giné E; Bladé J; Esteve J; Rosiñol L; Fernández-Avilés F; Marin P; Martinez C; Rovira M; Urbano-Ispizua A; Carreras E; Montserrat E
    Bone Marrow Transplant; 2004 Jan; 33(1):61-4. PubMed ID: 14704657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploratory analysis of intensified conditioning as first line treatment for patients with high risk multiple myeloma.
    Bommier C; Talbot A; Harel S; Cuccuini W; Gérard L; Arnulf B
    Hematol Oncol; 2020 Oct; 38(4):517-522. PubMed ID: 32569436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation.
    Aladağ Karakulak E; Demiroğlu H; Büyükaşik Y; Turgut M; Aksu S; Sayinalp N; Haznedaroğlu IC; Özcebe OI; Göker H
    Turk J Med Sci; 2020 Dec; 50(8):1851-1856. PubMed ID: 32512672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.
    Kebriaei P; Madden T; Kazerooni R; Wang X; Thall PF; Ledesma C; Nieto Y; Shpall EJ; Hosing C; Qazilbash M; Popat U; Khouri I; Champlin RE; Jones RB; Andersson BS
    Biol Blood Marrow Transplant; 2011 Mar; 17(3):412-20. PubMed ID: 20674757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients.
    Palumbo A; Triolo S; Baldini L; Callea V; Capaldi A; De Stefano V; Grasso M; Liberati M; Lotesoriere C; Marcenò R; Marmont F; Musto P; Petrucci MT; Spriano M; Pileri A; Boccadoro M
    Haematologica; 2000 May; 85(5):508-13. PubMed ID: 10800168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome.
    Patriarca F; Damiani D; Fanin R; Grimaz S; Geromin A; Cerno M; Sperotto A; Silvestri F; Zaja F; Baccarani M
    Haematologica; 2000 Mar; 85(3):269-74. PubMed ID: 10702815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors.
    Hawkins D; Barnett T; Bensinger W; Gooley T; Sanders J
    Med Pediatr Oncol; 2000 May; 34(5):328-37. PubMed ID: 10797354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic stem cell transplants for multiple myeloma.
    Tricot G; Jagannath S; Vesole DH; Bracy D; Desikan KR; Siegel D; Barlogie B
    Leuk Lymphoma; 1996 Jun; 22(1-2):25-36. PubMed ID: 8724525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.
    Segeren CM; Sonneveld P; van der Holt B; Vellenga E; Croockewit AJ; Verhoef GE; Cornelissen JJ; Schaafsma MR; van Oers MH; Wijermans PW; Fibbe WE; Wittebol S; Schouten HC; van Marwijk Kooy M; Biesma DH; Baars JW; Slater R; Steijaert MM; Buijt I; Lokhorst HM;
    Blood; 2003 Mar; 101(6):2144-51. PubMed ID: 12456509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autotransplants in multiple myeloma: what have we learned?
    Vesole DH; Tricot G; Jagannath S; Desikan KR; Siegel D; Bracy D; Miller L; Cheson B; Crowley J; Barlogie B
    Blood; 1996 Aug; 88(3):838-47. PubMed ID: 8704239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.
    Moreau P; Facon T; Attal M; Hulin C; Michallet M; Maloisel F; Sotto JJ; Guilhot F; Marit G; Doyen C; Jaubert J; Fuzibet JG; François S; Benboubker L; Monconduit M; Voillat L; Macro M; Berthou C; Dorvaux V; Pignon B; Rio B; Matthes T; Casassus P; Caillot D; Najman N; Grosbois B; Bataille R; Harousseau JL;
    Blood; 2002 Feb; 99(3):731-5. PubMed ID: 11806971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.
    Tosi P; Zamagni E; Ronconi S; Benni M; Motta MR; Rizzi S; Tura S; Cavo M
    Leukemia; 2000 Jul; 14(7):1310-3. PubMed ID: 10914557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells.
    Lemoli RM; Fortuna A; Motta MR; Rizzi S; Giudice V; Nannetti A; Martinelli G; Cavo M; Amabile M; Mangianti S; Fogli M; Conte R; Tura S
    Blood; 1996 Feb; 87(4):1625-34. PubMed ID: 8608257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow up of sequential mobilisation and autologous transplantation with CD34-selected cells in multiple myeloma: a multimodality approach.
    Horvath N; Hahn U; Joshua D; Dyson P; Gibson J; Stevens J; Rawling T; Barrow L; Brown R; Stephens S; Gower G; Norman J; Mills B; To LB
    Intern Med J; 2004 Apr; 34(4):167-75. PubMed ID: 15086696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.